NCT05130047View on ClinicalTrials.gov

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

November 8, 2022

Study Completion Date

November 8, 2022

Conditions
Chronic DiarrheaIrritable Bowel Syndrome With DiarrheaBile Acid MalabsorptionBile Acid DiarrheaBile Acid Malabsorption Syndrome Type IIFunctional Diarrhea
Interventions
DRUG

Aldafermin

1 mg solution

DRUG

Placebo

Aldafermin placebo solution

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors
All Listed Sponsors
collaborator

NGM Biopharmaceuticals, Inc

INDUSTRY

lead

Michael Camilleri, MD

OTHER

NCT05130047 - Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM) | Biotech Hunter | Biotech Hunter